Cambridge, Mass.-based Akcea Therapeutics priced its offering of 15.6 million shares at $8 apiece to reach its $125 million IPO target. The company initially priced an offering of 9.6 million shares at $12 to $14 per share.
Akcea’s shares are slated to begin trading on the Nasdaq exchange today under the “AKCA.”
Get the full story at our sister site, Drug Delivery Business News.
The post Ionis-spinout Akcea prices IPO below expected range appeared first on MassDevice.